Halozyme Signs Baxter

San Diego-based Halozyme Therapeutics announced that it has signed an exclusive agreement with Baxter Healthcare. Baxter will market, distribute, and sell Halozyme's recombinant human hyaluronidase enzyme in the United States and Puerto Rico, upon approval from the FDA. The company's new product is designed to enhance the delivery of local anesthesia and other applications. Terms of the deal were not disclosed.